Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.

Victor Virlogeux,Pascale Berthillon,Isabelle Bordes,Sylvie Larrat, Stéphanie Crouy,Caroline Scholtès,Pierre Pradat,Marianne Maynard,Fabien Zoulim,Vincent Leroy,Isabelle Chemin,Christian Trépo,Marie-Anne Petit

Clinics and Research in Hepatology and Gastroenterology（2018）

引用 0|浏览38

暂无评分

摘要

•Presence of anti-E1E2 antibody is associated with a lower baseline HCV viral load (<6log).•Presence of anti-E1E2 prior DAA-treatment is a predictive factor of SVR.•Absence of anti-E1E2 at baseline could predict DAA-treatment failure.•Anti-E1E2 monitoring could help to optimize DAAs’ duration and re-treatment options.

查看译文

关键词

Hepatitis C,Relapse,Direct-acting antivirals,Neutralizing antibodies,Sustained virological response,E1E2 envelope

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要